Literature DB >> 7186327

A new rating scale for dementia syndromes.

C G Gottfries, G Bråne, B Gullberg, G Steen.   

Abstract

A new scale, the GBS-scale, is constructed for rating dementia syndromes. The scale is divided into four subscales measuring motor, intellectual and emotional functions and different symptoms characteristic for dementia. The scale can be used by physicians, psychologists and registered nurses. The reliability of the scale is tested by rating 100 patients in somatic and psychogeriatric long-term care. The raters worked independently of each other and were recommended to confer with the staff about the status of the patient. The agreement between the raters was good. The validity of the scale was tested by comparing it with another geriatric rating scale. High correlations between the two scales were seen and indicated that the new scale measures dementia syndromes. The new scale measures degree of dementia and profiles of dementia syndromes. It is constructed in such a way that it can measure changes in dementia symptoms over a certain amount of time. Thus, it can be used in evaluating effect of treatment. It is not, however, meant to be a diagnostic scale.

Entities:  

Mesh:

Year:  1982        PMID: 7186327     DOI: 10.1016/0167-4943(82)90031-0

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  26 in total

Review 1.  Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.

Authors:  M Simard; R van Reekum
Journal:  Drugs Aging       Date:  1999-03       Impact factor: 3.923

Review 2.  The epidemiology of dementia: GMS-AGECAT studies of prevalence and incidence, including studies in progress.

Authors:  J R Copeland; M E Dewey; P Saunders
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

3.  The closure of a major psychiatric hospital. Characterization of the long-term population over one year at an early stage of deinstitutionalization.

Authors:  K Dencker; C G Gottfries
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1991-08       Impact factor: 4.328

Review 4.  Brain electrical activity (quantitative EEG and bit-mapping neurocognitive CNV components), psychometrics and clinical findings in presenile subjects with initial mild cognitive decline or probable Alzheimer-type dementia.

Authors:  R Zappoli; A Versari; M Paganini; G Arnetoli; G C Muscas; P F Gangemi; M G Arneodo; D Poggiolini; F Zappoli; A Battaglia
Journal:  Ital J Neurol Sci       Date:  1995-09

5.  The closure of a mental hospital in Sweden. 5 years of transition to district-based long-term care.

Authors:  K Dencker; G Långström
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

6.  Thiamine therapy in Alzheimer's disease.

Authors:  Y Mimori; H Katsuoka; S Nakamura
Journal:  Metab Brain Dis       Date:  1996-03       Impact factor: 3.584

7.  Parkinson's disease as community health problem: study in Norwegian nursing homes. The Norwegian Study Group of Parkinson's Disease in the Elderly.

Authors:  J P Larsen
Journal:  BMJ       Date:  1991-09-28

Review 8.  Towards defining restlessness in individuals with dementia.

Authors:  Natalie G Regier; Laura N Gitlin
Journal:  Aging Ment Health       Date:  2016-01-08       Impact factor: 3.658

9.  Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.

Authors:  David Wilkinson; Rachel Schindler; Elias Schwam; Gunhild Waldemar; Roy W Jones; Serge Gauthier; Oscar L Lopez; Jeffrey Cummings; Yikang Xu; Howard H Feldman
Journal:  Dement Geriatr Cogn Disord       Date:  2009-09-25       Impact factor: 2.959

10.  Fall-related injuries in a nursing home setting: is polypharmacy a risk factor?

Authors:  Federico Baranzini; Marcello Diurni; Francesca Ceccon; Nicola Poloni; Sara Cazzamalli; Chiara Costantini; Cristiano Colli; Laura Greco; Camilla Callegari
Journal:  BMC Health Serv Res       Date:  2009-12-11       Impact factor: 2.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.